Co-Authors
This is a "connection" page, showing publications co-authored by RUSSELL BROADDUS and KATHLEEN M SCHMELER.
Connection Strength
0.382
-
Progestin intrauterine device in an adolescent with grade 2 endometrial cancer. Obstet Gynecol. 2012 Feb; 119(2 Pt 2):423-426.
Score: 0.103
-
Primary peritoneal cancer after bilateral salpingo-oophorectomy in two patients with Lynch syndrome. Obstet Gynecol. 2010 Feb; 115(2 Pt 2):432-434.
Score: 0.090
-
Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 02; 224(2):191.e1-191.e15.
Score: 0.046
-
Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device. Obstet Gynecol. 2018 01; 131(1):109-116.
Score: 0.039
-
Clinically significant endometrial cancer risk following a diagnosis of complex atypical hyperplasia. Gynecol Oncol. 2014 Dec; 135(3):451-4.
Score: 0.031
-
Primary chemoprevention of endometrial hyperplasia with the peroxisome proliferator-activated receptor gamma agonist rosiglitazone in the PTEN heterozygote murine model. Int J Gynecol Cancer. 2008 Mar-Apr; 18(2):329-38.
Score: 0.020
-
Loss of phosphatase and tensin homologue deleted on chromosome 10 and phosphorylation of mammalian target of rapamycin are associated with progesterone refractory endometrial hyperplasia. Int J Gynecol Cancer. 2008 Jan-Feb; 18(1):146-51.
Score: 0.018
-
Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model. Am J Obstet Gynecol. 2007 Mar; 196(3):247.e1-5.
Score: 0.018
-
Women with synchronous primary cancers of the endometrium and ovary: do they have Lynch syndrome? J Clin Oncol. 2005 Dec 20; 23(36):9344-50.
Score: 0.017